Supplementary Figure S4 from IL4/IL13 Inhibition via Dupilumab Reduces Malignant T-cell Proliferation and Promotes Antitumor Immunity in Sézary Syndrome

Figure S4. B PF46 PF47 PF48 PF49 PF50 PF46 PF47 PF48 PF49 PF50 PF47 cl3 PF48 cl1 NA G tSNE1 p-value p–value and log2 FC NS HSP90AB1 BINIP3L 40 30 20 10 0 ZFP36L2 GAPDH LY6 CCT7 COTB IFI6 IL4R-2-1 0 PGK1 P4HA1 ALDOA 1 log2 fold change 2 C monocytes lymphocytes NKcells Bcells DCs HSPC H tSNE 1 I tSNE1 tSNE1 PF46 PF47 PF48 PF49 PF50 PF47 cl1 PF47 cl2 PF47 cl3 PF48 cl1 NA D PF46 PF47 PF48 PF49 PF50 J 2 1 0 2 1 0 IL13RA1 IL4R REGN668 UNT log2FC p-value p–value and log2 FC NS HSP90AB1 50 40 30 20 10 0 TUBA1B CCT5 SLC1A5 MTA2 GZMB-2-1 ZFP36L2 P4HA1 DDIT4 ALDOA ENO2 0 1 log2 fold change 2 Grouping of healthy control blood populations.